Risedronate prevents the loss of microarchitecture in glucocorticoid-induced osteoporosis in rats

Journal of Endocrinological Investigation

Volumn 30, Issue 9, 2007, Pages 739-746

  Dalle Carbonare, Luca ^a   Bertoldo, F ^a   Valenti, M T ^a   Zordan, S ^b   Sella, S ^b   Fassina, A ^b   Turco, G ^b   Realdi, G ^b   Lo Cascio, V ^a   Giannini, S ^b  

^a UNIVERSITY OF VERONA   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

Author keywords

Glucocorticoids; Histomorphometry; Microarchitecture; Rats; Risedronate; Secondary osteoporosis

Indexed keywords

GLUCOCORTICOID; METHYLPREDNISOLONE; RISEDRONIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE DENSITY; BONE STRUCTURE; CELL ACTIVITY; CONTROLLED STUDY; CORTICOSTEROID INDUCED OSTEOPOROSIS; DENSITOMETRY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; FEMALE; MORPHOMETRICS; NONHUMAN; OSTEOBLAST; RAT; TIBIA; TREATMENT DURATION;

EID: 36949027149     PISSN: 03914097     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03350811     Document Type: Article

References (42)

1. Reid IR. Glucocorticoid-induced osteoporosis: assessment and treatment. J Clin Densitom 1998, 1: 65-73.
2. Van Staa TP, Leufkens HGM, Abenhaim L, Zhang B, Cooper C. Use of Oral Corticosteroid and risk of fractures. J Bone Miner Res 2000, 15: 993-1000.
3. Adinoff AD, Hollister JR. Steroid-induced fracture and bone loss in patients with asthma. N Eng J Med 1983, 309: 265-8.
4. Cooper C, Coupland C, Mitchell M. Rheumatoid arthritis, corticosteroid therapy and hip fracture. Ann Rheum Dis 1995, 54: 49-52.
5. Saag KG, Emkey R, Schnitzer TJ, et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. N Engl J Med 1998, 339: 292-9.
6. Reid DM, Hughes RA, Laan RF, et al. Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study. J Bone Miner Res 2000, 15: 1006-13.
7. Adachi JD, Saag KG, Delmas PD, et al. Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial. Arthritis Rheum 2001, 44: 202-11.
8. Reid DM, Adami S, Devogelaer JP, Chines AA. Risedronate increases bone density and reduces vertebral fracture risk within one year in men on corticosteroid therapy. Calcif Tissue Int 2001, 69: 242-7.
9. Sambrook PN, Kotowicz M, Nash P, et al. Prevention and treatment of glucocorticoid-induced osteoporosis: a comparison of calcitriol, vitamin D plus calcium, and alendronate plus calcium. J Bone Miner Res 2003, 18: 919-24.
10. Erb N, Duncan RC, Raza K, et al. A regional audit of the prevention and treatment of corticosteroid-induced osteoporosis in patients with rheumatic diseases in the West Midlands. Rheumatology (Oxford) 2002, 41: 1021-4.
11. Walsh LJ, Lewis SA, Wong CA, et al. The impact of oral corticosteroid use on bone mineral density and vertebral fracture. Am J Respir Crit Care Med 2002, 166: 691-5.
12. Van Staa TP, Laan RF, Barton IP Cohen S, Reid DM, Cooper C. Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy. Arthritis Rheum 2003, 48: 3224-9.
13. Dempster DW. The contribution of trabecular architecture to cancellous bone quality. J Bone Miner Res 2000, 15: 20-3.
14. Weinstein RS, Chen JR, Powers CC, et al. Promotion of osteoclast survival and antagonism of bisphosphonate-induced osteoclast apoptosis by glucocorticoids. J Clin Invest 2002, 109: 1041-8.
15. Manolagas SC. Birth and death of bone cells: Basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr Rev 2000, 21: 115-37.
16. Chappard D, Legrand E, Basle MF, et al. Altered trabecular architecture induced by corticosteroids: A bone histomorphometric study. J Bone Miner Res 1996, 11: 676-85.
17. Dalle Carbonare L, Arlot ME, Chavassieux PM, Roux JP, Portero NR, Meunier PJ. Comparison of trabecular bone microarchitecture and remodelling in glucocorticoid-induced and postmenopausal osteoporosis. J Bone Miner Res 2001, 16: 97-103.
18. Canalis E, Delany AM. Mechanisms of glucocorticoid action in bone. Ann NY Acad Sci 2002, 966: 73-81.
19. O'Brien CA, Jia D, Plotkin Ll, et al. Glucocorticoids act directly on osteoblasts and osteocytes to induce their apoptosis and reduce bone formation and strength. Endocrinology 2004, 145: 1835-41.
20. Plotkin Ll, Weinstein RS, Parfitt AM, Roberson PK, Manolagas SC, Bellido T. Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin. J Clin Invest 1999, 104: 1363-74.
21. Bressot C, Meunier PJ, Chapuy MC, Lejeune E, Edouard C, Darby AJ. Histomorphometric profile, pathophysiology and reversibility of corticosteroid-induced osteoporosis. Metab Bone Dis Rel Res 1979, 1: 303-11.
22. Chavassieux PM, Arlot ME, Roux JP, wt al. Effects of alendronate on bone quality and remodeling in glucocorticoid-induced osteoporosis: a histomorphometric analysis of transiliac biopsies. J Bone Miner Res 2000, 15: 754-62.
23. Borah B, Dufresne TE, Chmielewski PA, Gross GJ, Prenger MC, Phipps RJ. Risedronate preserves trabecular architecture and increases bone strength in vertebra in ovariectomized minipigs as measured by three-dimensional microcomputed thomography. J Bone Miner Res 2002, 17: 1139-47.
24. Kimmel DB. Quantitative histologic changes in the proximal tibial growth cartilage of aged female rats. Scanning Microsc 1991, suppl 1: 11-8.
25. Parfitt AM, Drezner MK, Glorieux FH, et al. Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 1987, 6: 595-610.
26. Mellish RW, Ferguson-Pell MW, Cochran GV, Lindsay R, Dempster DW. A new manual method for assessing two-dimensional cancellous bone structure: comparison between iliac crest and lumbar vertebra. J Bone Miner Res 1991, 6: 689-96.
27. Vesterby A, Gundersen HJG, Melsen F. Starvolume of marrow space and trabeculae of the first lumbar vertebra: sampling efficiency and biological variation. Bone 1989, 10: 7-13.
28. Weinstein RS, Majumdar S. Fractal geometry and vertebral compression fractures. J Bone Miner Res 1994, 9: 1797-802.
29. Aaron JE, Makins NB, Sagreiya K. The microanatomy of trabecular bone loss in normal aging men and women. Clin Orthop Related Res 1987, 215: 260-71.
30. Li XJ, Jee WSS, Ke HZ, Mori S, Akamine T. Age-related changes of cancellous and cortical bone histomorphometry in female Sprague-Dawley rats. Scanning Microsc 1991, suppl 1: 25-35.
31. Chavassieux P, Pastoureau P, Chapuy MC, Delmas PD, Meunier PJ. Glucocorticoid-induced inhibition of osteoblastic bone formation in ewes: a biochemical and histomorphometric study. Osteoporos Int 1993, 3: 97-102.
32. Dempster DW, Arlot MA, Meunier PJ. Mean wall thickness and formation period of trabecular bone packets in corticosteroid osteoporosis. Calcif Tissue Int 1983, 35: 410-7.
33. Dalle Carbonare L, Valenti MT, Bertoldo F, et al. Bone microarchitecture evaluated by histomorphometry. Micron 2005, 36: 609-16.
34. Dalle Carbonare L, Giannini S. Bone microarchitecture as a determinant of bone strength. J Endocrinol Invest 2004, 27: 99-105.
35. Borah B, Dufresne TE, Chmielewski PA, Johnson TD, Chines A, Manhart MD. Risedronate preserves bone architecture in postmenopausal women with osteoporosis as measured by three-dimensional microcomputed tomography. Bone 2004, 34: 736-46.
36. Frost HM, Jee WS. On the rat model of human osteopenias and osteoporoses. Bone Miner 1992, 18: 227-36.
37. Mosekilde L. Assessing bone quality - animal models in preclinical osteoporosis research. Bone 1995, 17 (Suppl 4): 343S-52S.
38. Audran M, Chappard D, Legrand E, Libouban H, Baslé MF. Bone microarchitecture and bone fragility in men: DXA and histomorphometry in humans and in the orchiectomized rat model. Calcif Tissue Int 2001, 69: 214-7.
39. Nakamuta H, Nitta T, Hoshino T, Koida M. Glucocorticoid-induced osteopenia in rats: histomorphometrical and microarchitectural characterization and calcitonin effect. Biol Pharm Bull 1996, 19: 217-9.
40. Wimalawansa SJ, Simmons DJ. Prevention of corticosteroid-induced bone loss with alendronate. Proc Soc Exp Biol Med 1998, 217: 162-7.
41. Hulley PA, Conradie MM, Langeveldt CR, Hough FS. Glucocorticoid-induced osteoporosis in the rat is prevented by the tyrosine phosphatase inhibitor, sodium orthovanadate. Bone 2002, 31: 220-9.
42. Mosekilde L, Thomsen JS, Mackey MS, Phipps RJ. Treatment with residronate or alendronate prevents hind-limb immobilization-induced loss of bone density and strength in adult female rats. Bone 2000, 27: 639-45.